Published in Cancer Weekly, November 5th, 2002
Under the agreement, BioReliance will perform a range of assays for certain of MedImmune's development-stage or commercial products for a period of 1 year.
Capers McDonald, BioReliance president and CEO, said, "MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. We look forward to expanding our relationship with them through this most recent agreement, under which we will provide a broadened suite of advanced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.